Ozaslan, ErsinKaraca, HalitKoca, SinanSevinc, AlperHacioglu, BekirOzkan, MetinOzcelik, Melike2024-06-122024-06-1220170959-49731473-5741https://doi.org/10.1097/CAD.0000000000000445https://hdl.handle.net/20.500.14551/19708The objectives of this study were to compare progression-free survival (PFS) with somatostatin analog (SSA) versus chemotherapy (CTx) in first-line therapy and to determine the patient group in which these treatments were more effective in neuroendocrine tumors (NETs) with a Ki-67 index of 20% or less. Patients who received SSA or CTx and had unresectable locally advanced and metastatic NETs with a Ki-67 index of 20% or less were retrospectively selected from 13 centers in the Turkish database between 2000 and 2015. One hundred and sixty-five patients were enrolled. The median age was 56 years and the male-to-female ratio was 1.09. Seventy-four (45%) patients were of grade 1 NET and 91 (55%) were of grade 2. SSA was given to 104 patients, whereas 61 were treated with CTx. The objective response rate after SSA was 15.4%; another 73.1% had stable disease. The objective response rate after CTx was 36.1%, and 40.9% had stable disease (P = 0.008). The median PFS in SSA patients was 21 months (95% confidence interval: 12.4-29.6), and 8 months for CTx (95% confidence interval: 5.5-10.6) (P < 0.001). There was no significant difference between PFS of receiving SSA and CTx in pancreatic neuroendocrine tumor (PNET) patients; however, the PFS of receiving SSA was longer in non-PNET patients (P < 0.001). SSA was better treatment in advanced NET patients with a Ki-67 index of less than 5%, having a primary resected and a performance status of 0 (P < 0.05). SSA may be preferred over CTx in advanced NET patients with low-to-intermediate grade. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.en10.1097/CAD.0000000000000445info:eu-repo/semantics/closedAccessChemotherapyKi-67 IndexLanreotideNeuroendocrine TumorOctreotidePancreatic Neuroendocrine TumorSomatostatin AnalogCarcinoid-TumorsGrading SystemOctreotideLanreotideMidgutIndexArticle282222229Q3WOS:0003928240000122-s2.0-8499209287527768606Q3